Clinical Studies, Regulatory Clearance, Financial Results, and Approvals - Research Report on Bristol-Myers Squibb, Merck & Co.,

  Clinical Studies, Regulatory Clearance, Financial Results, and Approvals -
   Research Report on Bristol-Myers Squibb, Merck & Co., Johnson & Johnson,
                             AbbVie, and Novartis

PR Newswire

NEW YORK, October 31, 2013

NEW YORK, October 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting
Bristol-Myers Squibb Company (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK),
Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), and Novartis AG
(NYSE: NVS). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Bristol-Myers Squibb Company Research Report

On October 28, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and
Alder Biopharmaceuticals announced the presentation of efficacy and safety
data from a Phase IIb dose-ranging study of subcutaneous (SC) clazakizumab in
adults with moderate-to-severe rheumatoid arthritis (RA) and an inadequate
response to methotrexate (MTX). Bristol-Myers Squibb stated that Clazakizumab
is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6
cytokine rather than its receptor. The Company informed that all clazakizumab
treatment arms, both as monotherapy as well as in combination with
methotrexate (MTX), met the primary endpoint of ACR20 response at 12 weeks,
compared to MTX alone. Bristol-Myers Squibb stated that it has exclusive
worldwide rights to develop and commercialize clazakizumab for all indications
outside of cancer under a collaboration agreement with its discoverer, Alder
Biopharmaceuticals. The Full Research Report on Bristol-Myers Squibb Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

Merck & Co. Inc. Research Report

On October 28, 2013, Merck & Co. Inc. (Merck & Co.) reported its Q3 2013
financial results. Total sales decreased c.4% YoY to $11.0 billion. Net income
attributable to Merck & Co. was reported at $1.1 billion or $0.38 per diluted
share for Q3 2013, compared to $1.7 billion or $0.56 per diluted share in Q3
2012. Chairman and CEO Kenneth C. Frazier said, "This quarter we delivered
solid financial results, with strong contributions from our vaccine,
immunology and HIV businesses, and effective cost management. We are
encouraged that our combination hepatitis C regimen has joined our anti-PD-1
immunotherapy in being designated as a 'breakthrough therapy' by the FDA." For
full-year 2013, the Company targets to achieve an EPS of $1.61 to $1.79. The
Full Research Report on Merck & Co. Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]

Johnson & Johnson Research Report

On October 28, 2013, Ethicon Endo-Surgery, Inc. (Ethicon), a Johnson & Johnson
(Johnson & Johnson) Company, announced that HARMONIC ACE+ 7 Shears with
Advanced Hemostasis (HARMONIC ACE +7) has received 510(k) clearance from the
US FDA. According to the Company, HARMONIC ACE+ 7 is the first ultrasonic
surgical device indicated to seal vessels up to and including 7mm, while also
delivering on the HARMONIC promise of precision and multi-functionality. The
Company stated that the HARMONIC ACE+ 7 represents the latest evolution in the
HARMONIC legacy of innovation and leverages the proprietary Adaptive Tissue
Technology, which enables the system to actively sense and adapt to changing
tissue conditions and intelligently deliver energy resulting in improved
performance with superior precision. The Full Research Report on Johnson &
Johnson - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

AbbVie Inc. Research Report

On October 25, 2013, AbbVie Inc. (AbbVie) reported its Q3 2013 financial
results. Net sales increased 3.3% YoY to $4.7 billion. Net earnings were
$964.0 million or $0.60 per diluted share in Q3 2013, compared to $1.6 billion
or $1.01 per diluted share in Q3 2012. Chairman and CEO Richard A. Gonzalez
said, "Our third-quarter performance demonstrates the strength and durability
of our product portfolio and the continued execution of our key strategic
priorities as an independent biopharmaceutical company. Our mid- to late-stage
pipeline contains a number of potentially significant opportunities, and we
look forward to a series of milestones across our pipeline in the coming
months." For full-year 2013, the Company revised its diluted EPS guidance to
$2.54 to $2.56. The Full Research Report on AbbVie Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/273c_ABBV]

Novartis AG Research Report

On October 23, 2013, Novartis AG (Novartis) reported that Alcon, the second
largest division of the Company, has received positive recommendation from
National Institute for Health and Care Excellence (NICE) for Jetrea
(ocriplasmin) as a clinically and cost-effective treatment option for eligible
patients suffering from vitreomacular traction including when associated with
macular hole. The Company informed that with this final NICE guidance, Jetrea
is now recommended for use within the National Health Service (NHS) in England
and Wales as the first and only pharmacological treatment for this
sight-threatening eye condition. Stuart Raetzman, Area President Europe,
Middle East and Africa, Alcon, commented, "We are very pleased by the NICE
decision, as Jetrea® represents a breakthrough treatment option for patients
in the UK, which is now recommended for use in the NHS." The Full Research
Report on Novartis AG - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas : +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.